PDCD1 and neoplasm: These findings were supported in a preclinical mouse model, where PD-1 blockade reversed glucose restriction, allowing glucose influx and glycolysis with stimulated mTOR signaling, and eventual IFN-γ production, resulting in improved effector anti-tumor function.